Recruiting
Phase 1
Phase 2

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Sponsor:

St. Jude Children's Research Hospital

Code:

NCT04923126

Conditions

Low-Grade Glioma

Recurrent Low-Grade Glioma

Progressive Low-Grade Glioma

Eligibility Criteria

Sex: All

Age: 2 - 24

Healthy Volunteers: Not accepted

Interventions

Mirdametinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by St. Jude Children's Research Hospital on 2025-03-25.